Alumis (NASDAQ:ALMS) Stock Price Up 6.6% Following Insider Buying Activity

Alumis Inc. (NASDAQ:ALMS)’s share price rose 6.6% during trading on Wednesday after an insider bought additional shares in the company. The stock traded as high as $23.94 and last traded at $23.5690. Approximately 1,274,140 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 11,453,423 shares. The stock had previously closed at $22.11.

Specifically, Director Srinivas Akkaraju purchased 588,235 shares of the firm’s stock in a transaction dated Friday, January 9th. The stock was acquired at an average cost of $17.00 per share, with a total value of $9,999,995.00. Following the acquisition, the director owned 1,853,488 shares of the company’s stock, valued at approximately $31,509,296. This represents a 46.49% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Foresite Labs, Llc acquired 411,764 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $6,999,988.00. Following the purchase, the insider owned 5,702,536 shares of the company’s stock, valued at $96,943,112. This trade represents a 7.78% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In related news, Director James B. Tananbaum bought 411,764 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the completion of the purchase, the director directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. The trade was a 7.78% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Analysts Set New Price Targets

ALMS has been the topic of a number of research reports. UBS Group reiterated an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Oppenheimer reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Alumis in a research report on Tuesday, January 6th. Leerink Partners boosted their price target on shares of Alumis from $20.00 to $32.00 and gave the company an “outperform” rating in a report on Tuesday, January 6th. Morgan Stanley upped their price target on shares of Alumis from $22.00 to $33.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 7th. Finally, Guggenheim lifted their price objective on shares of Alumis from $18.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Director Srinivas Akkaraju bought 588,235 shares at $17 (~$10.0M), raising his stake to ~1.85M shares — a large insider purchase that signals management confidence and likely helped lift sentiment. SEC Filing – Akkaraju purchase
• Positive Sentiment: Director James B. Tananbaum acquired 411,764 shares at $17 (~$7.0M), boosting his holdings to ~5.70M shares — another high‑profile insider buy that supports upside momentum. SEC Filing – Tananbaum purchase
• Positive Sentiment: Major shareholder Foresite (Labs/Capital/Management entities) purchased 411,764 shares at $17 (~$7.0M), increasing its position — institutional buying usually improves liquidity and investor confidence. SEC Filing – Foresite purchase
• Positive Sentiment: Positive plaque‑psoriasis trial results for lead candidate Envudeucitinib drove a sharp re‑rating in recent weeks (the story says the stock ran from ~$5 to ~$20 in ~60 days), providing clinical validation that underpins investor enthusiasm. RTTNews – Plaque psoriasis data
• Neutral Sentiment: Multiple sell‑side firms have raised targets and reiterated buy/outperform views (consensus remains a “Moderate Buy”), which amplifies momentum but may already be priced in. MarketBeat analyst coverage
• Neutral Sentiment: Reported short‑interest data for January appears anomalous/zero in recent entries, so short‑interest signals are unreliable as a contrarian indicator right now. Market data
• Negative Sentiment: Fundamental caution: Alumis missed on the most recent reported quarter (Nov. 13) — EPS and revenue were below consensus and the company remains unprofitable, leaving the stock exposed if future clinical or execution results disappoint. Earnings/Background

Alumis Trading Up 8.4%

The business’s 50-day simple moving average is $9.90 and its 200 day simple moving average is $6.21. The company has a market capitalization of $2.50 billion, a P/E ratio of -5.89 and a beta of -2.09.

Alumis (NASDAQ:ALMS) last announced its earnings results on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. As a group, sell-side analysts predict that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Institutional Trading of Alumis

Institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after acquiring an additional 4,894 shares in the last quarter. CWM LLC grew its stake in shares of Alumis by 1,028.7% in the 3rd quarter. CWM LLC now owns 10,384 shares of the company’s stock worth $41,000 after purchasing an additional 9,464 shares during the last quarter. Kera Capital Partners Inc. acquired a new position in shares of Alumis in the 2nd quarter worth approximately $32,000. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Alumis by 199.7% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company’s stock worth $32,000 after purchasing an additional 7,165 shares in the last quarter. Finally, New York State Common Retirement Fund lifted its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after purchasing an additional 7,467 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.